PURPOSE: To develop and assess a technique for induction of C peptide-negative diabetes in adult nonhuman primates in preparation for preclinical investigation of type 1 diabetes treatments. MATERIALS AND METHODS: First, temporary embolization of the hepatic and gastric arteries was performed in 14 adult nonhuman primates (six cynomolgus, five rhesus, and three pigtail macaques). After embolization was confirmed with angiography, streptozotocin was injected at a dose of 50-70 mg/kg into the celiac artery and branches supplying the pancreas. The macaques then were given intravenous injections of arginine and glucose, and blood levels of insulin and C peptide were measured with an enzyme-linked immunosorbent assay to determine whether diabetes had been induced. RESULTS: All but one of the macaques developed persistent long-term C peptide-negative diabetes after the streptozotocin injection. One macaque did not develop diabetes after the initial injection and was given a second dose of streoptozotocin, which did induce diabetes. None of the macaques showed any symptoms of hepatic or renal injury, and only one died (of gastric dilatation 5 days after the procedure). CONCLUSION: Streptozotocin injection after temporary embolization of the hepatic and gastric arteries is a safe and reproducible method for inducing C peptide-negative diabetes in adult nonhuman primates in preparation for preclinical investigation of type 1 diabetes treatments. Copyright RSNA, 2003
PURPOSE: To develop and assess a technique for induction of C peptide-negative diabetes in adult nonhuman primates in preparation for preclinical investigation of type 1 diabetes treatments. MATERIALS AND METHODS: First, temporary embolization of the hepatic and gastric arteries was performed in 14 adult nonhuman primates (six cynomolgus, five rhesus, and three pigtail macaques). After embolization was confirmed with angiography, streptozotocin was injected at a dose of 50-70 mg/kg into the celiac artery and branches supplying the pancreas. The macaques then were given intravenous injections of arginine and glucose, and blood levels of insulin and C peptide were measured with an enzyme-linked immunosorbent assay to determine whether diabetes had been induced. RESULTS: All but one of the macaques developed persistent long-term C peptide-negative diabetes after the streptozotocin injection. One macaque did not develop diabetes after the initial injection and was given a second dose of streoptozotocin, which did induce diabetes. None of the macaques showed any symptoms of hepatic or renal injury, and only one died (of gastric dilatation 5 days after the procedure). CONCLUSION:Streptozotocin injection after temporary embolization of the hepatic and gastric arteries is a safe and reproducible method for inducing C peptide-negative diabetes in adult nonhuman primates in preparation for preclinical investigation of type 1 diabetes treatments. Copyright RSNA, 2003
Authors: Kylie Kavanagh; David M Flynn; Chris Nelson; Li Zhang; Janice D Wagner Journal: J Pharmacol Toxicol Methods Date: 2011-02-26 Impact factor: 1.950
Authors: Patrice A Frost; Shuyuan Chen; Marguerite J Mezzles; Venkata Saroja Voruganti; Edna J Nava-Gonzalez; Hector E Arriaga-Cazares; Katy A Freed; Anthony G Comuzzie; Ralph A DeFronzo; Jack W Kent; Paul A Grayburn; Raul A Bastarrachea Journal: J Med Primatol Date: 2015-06-30 Impact factor: 0.667
Authors: Scott A Soleimanpour; Boaz Hirshberg; David J Bunnell; Anne E Sumner; Marilyn Ader; Alan T Remaley; Kristina I Rother; Michael R Rickels; David M Harlan Journal: Cell Transplant Date: 2011-11-11 Impact factor: 4.064
Authors: A Casu; R Bottino; A N Balamurugan; H Hara; D J van der Windt; N Campanile; C Smetanka; D K C Cooper; M Trucco Journal: Diabetologia Date: 2007-10-25 Impact factor: 10.122
Authors: Bas Brouwers; Vincent P E G Pruniau; Elisa J G Cauwelier; Frans Schuit; Evelyne Lerut; Nadine Ectors; Jeroen Declercq; John W M Creemers Journal: J Biol Chem Date: 2013-08-11 Impact factor: 5.157
Authors: Rafael Latorre; Wendy Hernández; Fei Sun; Francisco Sánchez-Margallo; Francisco Gil; Octavio López-Albors; Jose M Vázquez; Jesús Usón Journal: Exp Diabetes Res Date: 2011-10-04